Ascendis Pharma A/S
Stock Forecast, Prediction & Price Target
Ascendis Pharma A/S Financial Estimates
Ascendis Pharma A/S Revenue Estimates
Ascendis Pharma A/S EBITDA Estimates
Ascendis Pharma A/S Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $7.77M N/A | $51.17M 557.93% | $266.71M 421.19% | Avg: $656.41M Low: $561.30M High: $816.86M avg. 146.10% | Avg: $1.10B Low: $995.17M High: $1.28B avg. 68.55% | Avg: $1.84B Low: $1.65B High: $2.14B avg. 66.45% | Avg: $2.31B Low: $2.08B High: $2.69B avg. 25.92% |
Net Income
% change YoY
| $-383.57M N/A | $-583.19M -52.04% | $-481.44M 17.44% | Avg: $-5.01M Low: $-176.50M High: $241.44M avg. 98.95% | Avg: $318.74M Low: $53.42M High: $872.56M avg. 6456.78% | Avg: $717.72M Low: $623.91M High: $869.58M avg. 125.17% | Avg: $969.45M Low: $842.73M High: $1.17B avg. 35.07% |
EBITDA
% change YoY
| $-423.66M N/A | $-527.33M -24.46% | $-411.16M 22.02% | Avg: $-656.41M Low: $-816.86M High: $-561.30M avg. -59.64% | Avg: $-1.10B Low: $-1.28B High: $-995.17M avg. -68.55% | Avg: $-1.84B Low: $-2.14B High: $-1.65B avg. -66.45% | Avg: $-2.31B Low: $-2.69B High: $-2.08B avg. -25.92% |
EPS
% change YoY
| -$7 N/A | -$10.4 -48.57% | -$8.55 17.78% | Avg: -$0.37 Low: -$3.14 High: $4.29 avg. 95.67% | Avg: $5.39 Low: $0.95 High: $15.5 avg. 1558.28% | Avg: $12.75 Low: $11.08 High: $15.45 avg. 136.51% | Avg: $17.22 Low: $14.97 High: $20.87 avg. 35.07% |
Operating Expenses
% change YoY
| $456.04M N/A | $600.85M 31.75% | $677.86M 12.81% | Avg: $5.32B Low: $4.55B High: $6.62B avg. 685.51% | Avg: $8.97B Low: $8.07B High: $10.43B avg. 68.55% | Avg: $14.93B Low: $13.43B High: $17.37B avg. 66.45% | Avg: $18.81B Low: $16.92B High: $21.87B avg. 25.92% |
FAQ
What is Ascendis Pharma A/S stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 1678.99% in 2025-2028.
We have gathered data from 7 analysts. Their low estimate is -176.50M, average is -5.01M and high is 241.44M.
What is Ascendis Pharma A/S stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 76.76% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $561.30M, average is $656.41M and high is $816.86M.
What is Ascendis Pharma A/S stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 456.38% in 2025-2028.
We have gathered data from 7 analysts. Their low earnings per share estimate is -$3.14, average is -$0.37 and high is $4.28.
What is the best performing analyst?
In the last twelve months analysts have been covering Ascendis Pharma A/S stock. The most successful analyst is Alex Thompson.